Proxy Votes Now

Home › Funds › BlackRock › BlackRock Health Sciences Opportunities Portfolio

BlackRock Health Sciences Opportunities Portfolio (SHISX) proxy voting record 2025-2026

Fund family: BlackRock · Filed by BLACKROCK FUNDS (CIK 844779) · SEC series S000001877

Share classes and tickers: SHISX (C000004913), SHSAX (C000004914), SHSCX (C000004916), SHSSX (C000004912)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,146 with, 25 against, 18 abstentions (not counted as with management); 5 items carried no recommendation. Shareholder proposals: 0 FOR, 25 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with BlackRock as a whole

The same two figures as BlackRock’s manager page (1,606,521 ballot items across 392 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsBlackRockItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)96.4%1,10193.6%1,355,861
Backed environmental and social shareholder proposals at US companiesn/a55.5%6,306

Where this fund voted differently from most BlackRock funds

Each ballot item this fund voted is set against the votes of the other BlackRock funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most BlackRock funds on 36 items (3.2% of the 1,109 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost BlackRock fundsMgmtResult
GE HEALTHCARE TECHNOLOGIES INC.2026-05-07Election of Directors Catherine LesjakAgainstFOR — 35 of 38 BlackRock fundsAgainst—
ROIVANT SCIENCES LTD.2025-09-10To cast a non-binding, advisory vote to approve the compensation of our named executive officers.ForAGAINST — 32 of 35 BlackRock fundsForApproved, 60.9% support
THE COOPER COMPANIES, INC.2026-04-07Approve, on a non-binding, advisory basis, the compensation of our Named Executive Officers.AgainstFOR — 48 of 56 BlackRock fundsAgainstApproved, 89.9% support
HUMANA INC.2026-04-16Election of Directors Wayne A. I. Frederick, M.D.ForAGAINST — 41 of 48 BlackRock fundsFor—
BIO-TECHNE CORP2025-10-30Approve, on an advisory basis, the compensation of our executive officers.AgainstFOR — 35 of 42 BlackRock fundsAgainstApproved, 72.1% support
HOLOGIC, INC.2026-02-05A proposal to approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to the named executive officers of the Company in connection with the transactions contemplated by the merger agreement, including consummation of the merger.ForAGAINST — 50 of 64 BlackRock fundsFor—
DENALI THERAPEUTICS INC.2026-06-03DIRECTOR: Jennifer CookForABSTAIN — 15 of 17 BlackRock fundsFor—
INCYTE CORPORATION2026-06-08Approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.ForAGAINST — 54 of 73 BlackRock fundsForApproved, 83.9% support
EXACT SCIENCES CORPORATION2026-02-20Proposal to approve, on an advisory (nonbinding) basis, the compensation that may be paid or become payable to Exact Sciences Corporation's named executive officers that is based on or otherwise related to the Merger Agreement and the transactions contemplated by the Merger Agreement (the "CompensatForAGAINST — 31 of 40 BlackRock fundsFor—
INCYTE CORPORATION2026-06-08Election of Directors to serve until the 2027 annual meeting of shareholders and thereafter until their successors are duly elected and qualified: Jean-Jacques BienaiméForAGAINST — 44 of 60 BlackRock fundsFor—
KODIAK SCIENCES INC.2026-06-02Elect three Class II directors nominated by our board and named in this proxy statement. Charles A. BancroftWithholdFOR — 12 of 14 BlackRock fundsAgainst—
WAVE LIFE SCIENCES LTD.2025-08-05To authorize the Board of Directors to allot and issue Ordinary Shares of Wave Life Sciences Ltd.AgainstFOR — 14 of 17 BlackRock fundsAgainstApproved, 78.2% support
RADNET, INC.2026-06-02DIRECTOR: Laura P. JacobsAbstainFOR — 17 of 22 BlackRock fundsAgainst—
GALDERMA GROUP AG2026-04-22Approve Remuneration Report (Non-Binding)AgainstFOR — 31 of 43 BlackRock fundsAgainst—
SUMMIT THERAPEUTICS INC.2026-06-10Approval of an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to Increase the Number of Shares of Common Stock.ForAGAINST — 14 of 18 BlackRock fundsForPassed (calculated), 95.8% support
SUMMIT THERAPEUTICS INC.2026-06-10DIRECTOR: Kenneth A. ClarkForABSTAIN — 14 of 18 BlackRock fundsFor—
APOGEE THERAPEUTICS, INC.2026-06-09DIRECTOR: William (BJ) Jones, Jr.ForABSTAIN — 12 of 15 BlackRock fundsFor—
SCHOLAR ROCK HOLDING CORPORATION2026-06-04DIRECTOR: Kristina BurowForABSTAIN — 14 of 19 BlackRock fundsFor—
DYNE THERAPEUTICS, INC.2026-06-05To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified. Jason RhodesWithholdFOR — 14 of 19 BlackRock fundsAgainst—
AVIDITY BIOSCIENCES, INC.2026-02-26To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to our named executive officers in connection with the transactions contemplated by the Merger Agreement and the Separation Agreement.ForAGAINST — 23 of 34 BlackRock fundsForApproved, 82.4% support
VIKING THERAPEUTICS INC2026-05-19TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.ForAGAINST — 25 of 38 BlackRock fundsForApproved, 70.2% support
PROTAGONIST THERAPEUTICS, INC.2026-06-17DIRECTOR: L.T. Williams, MD, PhDAbstainFOR — 19 of 28 BlackRock fundsAgainst—
NOVOCURE LIMITED2026-06-03The approval of our amended and restated 2024 Omnibus Incentive Plan.AgainstFOR — 13 of 18 BlackRock fundsAgainstApproved, 50.3% support
BRIGHT MINDS BIOSCIENCES INC.2026-03-31DIRECTOR: David WeinerAbstainFOR — 8 of 10 BlackRock fundsAgainst—
BRIGHT MINDS BIOSCIENCES INC.2026-03-31DIRECTOR: Jan PedersenAbstainFOR — 8 of 10 BlackRock fundsAgainst—
Show all 36
Items 26 to 36.
CompanyMeetingItemThis fundMost BlackRock fundsMgmtResult
BRIGHT MINDS BIOSCIENCES INC.2026-03-31DIRECTOR: Jeremy FryzukAbstainFOR — 8 of 10 BlackRock fundsAgainst—
THERMO FISHER SCIENTIFIC INC.2026-05-20An advisory vote to approve named executive officer compensation.AgainstFOR — 40 of 67 BlackRock fundsAgainstNot approved, 31.8% support
GALDERMA GROUP AG2026-04-22Approve Remuneration of Executive Committee in the Amount of CHF 31.2 MillionAgainstFOR — 21 of 32 BlackRock fundsAgainst—
ZEALAND PHARMA A/S2026-03-26REELECT ALF GUNNAR MARTIN NICKLASSON AS DIRECTORForABSTAIN — 11 of 15 BlackRock fundsFor—
VIKING THERAPEUTICS INC2026-05-19DIRECTOR: J. Matthew SingletonForABSTAIN — 18 of 28 BlackRock fundsFor—
GALDERMA GROUP AG2026-04-22Transact Other Business (Voting)AbstainFOR — 20 of 32 BlackRock fundsAgainst—
MODERNA, INC.2026-05-06To approve, on a non-binding, advisory basis, the compensation of our named executive officers.AgainstFOR — 33 of 59 BlackRock fundsAgainstApproved, 65.1% support
MERUS N.V.2025-12-09Non-binding advisory proposal to approve certain compensation arrangementsForAGAINST — 12 of 19 BlackRock fundsForPassed (calculated), 55.9% support
ZEALAND PHARMA A/S2026-03-26AUTHORIZE SHARE REPURCHASE PROGRAMForABSTAIN — 8 of 12 BlackRock fundsFor—
ZEALAND PHARMA A/S2026-03-26ELECT IRIS LOEW FRIEDRICH AS NEW DIRECTORForABSTAIN — 8 of 12 BlackRock fundsFor—
ZEALAND PHARMA A/S2026-03-26REELECT ELAINE SULLIVAN AS DIRECTORForABSTAIN — 8 of 12 BlackRock fundsFor—

Download all 36 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 82.3% of this fund’s 1,189 such votes could be given a sector; the other 211 (17.7%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care885242.7%
Industrials7600.0%
Consumer Staples1715.9%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections7560
Say-on-Pay1320
Audit-related1290
Corporate Governance6314
Compensation541
Capital Structure330
Shareholder Rights and Defenses195
Extraordinary Transactions100
Other Social Issues94
Human Rights or Human Capital/workforce11

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
ELI LILLY AND COMPANYMay 4, 2026$1.0B102
JOHNSON & JOHNSONApril 23, 2026$760M151
MERCK & CO., INC.May 26, 2026$385M183
ABBVIE INC.May 8, 2026$341M81
GILEAD SCIENCES, INC.April 30, 2026$291M153
UNITEDHEALTH GROUP INCORPORATEDJune 1, 2026$279M121
AMGEN INC.May 19, 2026$272M151
EDWARDS LIFESCIENCES CORPORATIONMay 7, 2026$183M120

Notable votes against management

MeetingCompanyProposalFundMgmt
May 4, 2026ELI LILLY AND COMPANYShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalAgainstFor
May 4, 2026ELI LILLY AND COMPANYShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
April 23, 2026JOHNSON & JOHNSONIndependent Board Chair Shareholder proposalAgainstFor
May 26, 2026MERCK & CO., INC.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026MERCK & CO., INC.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
May 8, 2026ABBVIE INC.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalAgainstFor
April 30, 2026GILEAD SCIENCES, INC.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
April 30, 2026GILEAD SCIENCES, INC.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
June 1, 2026UNITEDHEALTH GROUP INCORPORATEDIf properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposalAgainstFor
May 19, 2026AMGEN INC.Stockholder proposal to require an independent board chairman. Shareholder proposalAgainstFor
May 13, 2026VERTEX PHARMACEUTICALS INCORPORATEDShareholder Proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalAgainstFor
May 5, 2026BRISTOL-MYERS SQUIBB COMPANYShareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director Shareholder proposalAgainstFor

Search this fund’s votes by company

1,206 ballot items at 138 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, BlackRock Health Sciences Opportunities Portfolio (SHISX) voted at 138 shareholder meetings of 131 companies, on 1,206 ballot items in all. Where management made a recommendation, the fund followed it on 96.4% of the items and voted against it 25 times. Its most frequent area of disagreement was corporate governance (14 of its votes against management). It voted on 25 shareholder proposals. It voted FOR the board's own proposals more often than BlackRock's funds as a whole (96.4% against 93.6%). It voted differently from most BlackRock funds on 36 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of BlackRock’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.